---
title: 'Time from admission to randomization and the effect of empagliflozin in acute
  heart failure: A post-hoc analysis from EMPULSE'
date: '2024-07-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38980272/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240709184535&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among patients hospitalized for acute HF enrolled in EMPULSE,
  those randomized later after hospital admission (3-5 days) experienced greater clinical
  benefit with empagliflozin than those randomized earlier (1-2 days). These findings
  should be confirmed in future studies before clinical ...'
disable_comments: true
---
CONCLUSIONS: Among patients hospitalized for acute HF enrolled in EMPULSE, those randomized later after hospital admission (3-5 days) experienced greater clinical benefit with empagliflozin than those randomized earlier (1-2 days). These findings should be confirmed in future studies before clinical ...